Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Actuate Therapeutics Inc
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Group
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicil Development LLC
InnoBioscience LLC
Novosteo Inc
Park Active Molecules
Zovis Pharmaceuticals
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
9-ING41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
Glycogen Synthase Kise 3 Beta (Serine/Threonine Protein Kise GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Feb 11, 2020: Injectable drug for faster healing of bone fractures prepares for clinical trials
Sep 16, 2019: AMO Pharma participates in Workshop on central nervous system involvement in progression and treatment of Myotonic Dystrophy during Myotonic Dystrophy Foundation Annual Conference
Jun 13, 2019: Updates on development of AMO Pharma’s AMO-02 presented at Intertiol Myotonic Dystrophy Consortium Meeting
May 06, 2019: AMO Pharma presents statistical alysis of results of phase 2 study of AMO-02 in adolescents with autism spectrum disorder
Dec 17, 2018: Actuate Therapeutics opens phase 1/2 clinical study of 9-ING-41 in patients with refractory cancers
Oct 30, 2018: AMO Pharma reports positive results from AMO-02 trial
Oct 23, 2018: AMO Therapeutics announces presentation of concordant alysis of results of phase 2 study of AMO-02 in treatment of myotonic dystrophy
Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers
Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Desigtion for 9-ING-41 for Treatment of Neuroblastoma
Oct 18, 2017: AMO Pharma Presents Positive Interim Alysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Alysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study
Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Desigtion for AMO-02 for Treatment of Congenital Myotonic Dystrophy
May 30, 2017: AMO Pharma Announces FDA Fast Track Desigtion For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Apr 03, 2017: Actuate Therapeutics’ Programs Highlighted in Clinical Cancer Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Actuate Therapeutics Inc, H1 2020
Pipeline by Alzamend Neuro Inc, H1 2020
Pipeline by AMO Pharma Ltd, H1 2020
Pipeline by Angelini Group, H1 2020
Pipeline by Ankar Pharma SL, H1 2020
Pipeline by Avenzoar Pharmaceuticals Inc, H1 2020
Pipeline by CerebraMed, H1 2020
Pipeline by Collaborative Medicinal Development LLC, H1 2020
Pipeline by InnoBioscience LLC, H1 2020
Pipeline by Novosteo Inc, H1 2020
Pipeline by Park Active Molecules, H1 2020
Pipeline by Zovis Pharmaceuticals, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020